The Role of IκBα in TNF-α-induced Apoptosis in Hepatic Stellate Cell Line HSC-T6

To investigate the role of NF-κB in TNF-α induced apoptosis in HSC-T6, a mutant IκBα was transfected into HSC-T6 cells by lipofectin transfection technique and its transient effect was examined 48 h after the transfection. The activation of NF-κB was detected by immune fluorescence cytochemistry and Western blotting with anti-p65 antibody. The apoptosis and the rate of inhibition by TNF-α in both transfected and untransfected HSC-T6 cells were measured respectively by FAC-Scan side scatter analysis and MTF methods. Our results showed that TNF-α could activate NF-κB in untransfected cells but not in transfected HSC-T6 cells. The percentage of apoptosis in transfected cells were significantly higher than that in the untransfected ones （P〈0.01） and it was also true of the inhibition rate （P〈0.01）. It is concluded that the resistance of HSC-T6 towards apoptosis induced by TNF-α can be mediated by NF-κB activation. The inhibition of NF-κB activation by mutant IκBα can attenuate the resistance of HSC-T6 cells and increase its sensitivity to TNF-α.

肝动脉化疗栓塞联合安罗替尼治疗晚期肝癌的临床研究

目的观察肝动脉化疗栓塞术(TACE)联合安罗替尼与单独TACE治疗晚期肝癌的临床疗效差异。方法选择2018年6月至2019年1月期间在郑州大学第一附属医院住院治疗的晚期肝癌患者,按照是否口服安罗替尼的意愿,分为试验组和对照组,每组各21例,共42例。对照组只进行TACE治疗,试验组在TACE治疗的基础上从术后第4天开始口服安罗替尼12 mg/d,连续给药2周,暂停1周,21 d为1个疗程,分别评估TACE术后1个月、3个月后的疗效和不良反应。计量资料以均值±标准差(Mean±SD)表示,组间比较采用t检验;计数资料以率(%)表示,组间比较采用χ2检验,以P<0.05为差异有统计学意义。结果在TACE术后1个月,试验组和对照组的疾病控制率分别为90.5%、71.4%,差异无统计学意义(χ2=1.390,P>0.05)。而在TACE术后3个月,试验组的21例患者中,完全缓解4例,部分缓解6例,疾病稳定8例,疾病进展3例,疾病控制率为85.7%;对照组的21例患者中,完全缓解0例,部分缓解5例,疾病稳定7例,疾病进展9例,疾病控制率为57.1%,两组疾病控制率差异有统计学意义(χ2=4.200,P<0.05)。安罗替尼相关不良反应主要包括手足综合征(9/21,42.9%),高血压(4/21,19.0%),蛋白尿(5/21,23.8%),未发生3级以上毒性反应。结论TACE联合安罗替尼治疗晚期肝癌安全有效。